Inhibition of pancreatic glucagon secretion during hyperglycemia could be mediated by (a) glucose, (b) insulin, (c) somatostatin, or (d) glucose in conjunction with insulin. To determine the role of these factors in the mediation of glucagon suppression, we injected alloxan while clamping the arterial supply of the pancreatic splenic lobe of dogs, thus inducing insulin deficiency localized to the ventral lobe and avoiding hyperglycemia. Ventral lobe insulin, glucagon, and somatostatin outputs were then measured in response to a stepped IV glucose infusion. In control dogs glucagon suppression occurred at a glucose level of 150 mg/dl and somatostatin output increased at glucose > 250 mg/dl. In alloxan-treated dogs glucagon output was not suppressed nor did somatostatin output increase. We concluded that insulin was required in the mediation of glucagon suppression and somatostatin stimulation. Subsequently, we infused insulin at high rates directly into the artery that supplied the beta cell-deficient lobe in six alloxan-treated dogs. Insulin infusion alone did not cause suppression of glucagon or stimulation of somatostatin; however, insulin repletion during glucose infusions did restore the ability of hyperglycemia to suppress glucagon and stimulate somatostatin. We conclude that intra-islet insulin permits glucose to suppress glucagon secretion and stimulate somatostatin during hyperglycemia. (J. Clin. Invest.
Introduction
It has long been known that in healthy subjects glucagon secretion is suppressed by hyperglycemia; whereas, Type I diabetic patients have relatively elevated glucagon levels despite hyperglycemia. Hyperglucagonemia in turn perpetuates diabetic hyperglycemia because glucagon potently stimulates hepatic glucose output. This old observation of increased glucagon secretion in Type I diabetes has recently been bolstered by reports of increased levels ofglucagon mRNA in the pancreas ofdiabetic rats suggesting increased glucagon synthesis as well as secretion (1) .
The abnormal regulation of the A cell in Type I diabetes is presumably related to the insulin deficiency and resultant abnormal internal milieu ofthe diabetic islet. However, the exact mechanism responsible for this defect continues to be debated because ofconflicting studies and inadequate understanding of the mechanisms of glucagon suppression by hyperglycemia in the nondiabetic islet. Previous experiments in man and experimental animals have suggested at least four possible mechanisms ofA cell suppression during hyperglycemia. Thus, A cell suppression could be caused by: (a) glucose per se (2) (3) (4) (5) , (b) insulin (6-1 1), (c) pancreatic somatostatin (12) , or (d) an action of glucose to directly suppress glucagon secretion which is dependent on adequate islet insulin levels (13) . Such a permissive effect ofinsulin has recently been demonstrated in adipose tissue in which insulin exposure is required to maintain the biosynthesis of a glucose transporter ( 14) .
Advances in our understanding of both the microcirculation of the islet and the effects of chronic hyperglycemia on glucose recognition by islet cells emphasize some of the then unrecognized problems with the experimental design ofearlier experiments. For example, although in vitro studies ofisolated islets have had the advantage of strict control of the ambient glucose level, the question ofwhether these results are applicable to the in vivo situation has been raised by evidence ofdirectional islet blood flow (see below) (15). Previous in vivo methods, which are usually more physiologic, also had disadvantages. For example, to assess the role of insulin, B cell cytotoxins have been given to the whole animal which necessarily creates a chronic hyperglycemia. Recent evidence suggests that chronic hyperglycemia itselfcan decrease the sensitivity of B and A cells to acute glucose exposure (16) (17) (18) (19) (20) (21) (22) . Therefore, the chronically diabetic animal may not be the best model in which to determine if the acute glucose exposure per se can directly suppress the A cell under physiologic conditions in the nondiabetic animal. Finally, studies on islet microvasculature suggest that the A cell is downstream from the B cell and therefore presumably bathed by high concentrations of insulin (15). Thus, very high rates of local insulin infusions may be needed to adequately replace the insulin lost by chemical destruction of the beta cell. In previous studies the amount of insulin required for repletion has probably been underestimated.
In light of these newly recognized concerns, we developed an animal model, adopted from that of Gomori and Goldner (23), in which chronic beta cell deficiency was present only in the ventral lobe ofthe canine pancreas. The functioning dorsal lobe continued to secrete sufficient insulin to maintain fasting normoglycemia in these animals. We were then able to study the effects of acute increases of glucose on glucagon secretion from the B cell-deficient lobe in chronically euglycemic animals. Subsequently, we infused insulin at high rates directly into the pancreatic artery which supplied the beta cell deficient lobe in order to normalize the intra-islet insulin levels. We were thus able to assess the effect ofinsulin alone or in combination with acute hyperglycemia on the A cell now reexposed to high levels of intra-islet insulin.
Methods

Animals and surgery preparations
In the dog, the pancreas can be divided into three parts: the dorsal lobe supplied by branches of the splenic artery and vein, the ventral lobe which shares the blood supply of the proximal duodenum, and the embryologically-distinct uncinate process supplied by the inferior pancreatic artery and vein. Although the uncinate process is well known to be glucagon poor, the ventral lobe, studied in these experiments, has a glucagon content similar to the glucagon-rich dorsal lobe (24, 25) . (This was confirmed by measurements of glucagon content in our laboratory.) In these experiments the circulation to the dorsal lobe was transiently clamped during alloxan injection (see below) to protect its beta cells from destruction. The ventral lobe was exposed to the alloxan and became insulin deficient. Glucagon secretion was studied from the ventral lobe of non-alloxan-injected dogs, alloxan-injected dogs, and alloxan-injected, insulin-infused dogs (see below). (27) . Briefly, the superior pancreatico-duodenal vein, which drains the ventral lobe of the pancreas, was cannulated with a silastic catheter and bypassed through an electromagnetic flow probe and a sampling port into the portal vein. The small vascular branches between the duodenum and pancreas were ligated and cut. This allowed the measurement ofinsulin (I), glucagon (G), and pancreatic somatostatin (SS) output from the ventral pancreatic lobe without contamination by duodenal venous drainage. In addition, the femoral artery was cannulated for blood pressure recording and blood sampling.
In experimental protocol 2 (see below), the superior pancreaticoduodenal artery was also cannulated and infused with either saline or insulin at a rate of 0.2 ml/min. Experimental protocol I:four step glucose infusion. Secretion ofG, I, and SS from the control or insulin-deficient ventral lobe of the pancreas were measured in eight alloxan-treated and seven controls dogs in response to arginine and to four levels of increasing hyperglycemia. Blood Step three Insulin 50 10 Step four Insulin 200 40
Assays
Blood samples for assay of immunoreactive insulin (IRI) and glucose were drawn on EDTA, those for IRG on benzamidine and heparin (28) , and those for somatostatin-like immunoreactivity (SLI) on a mixture of anticoagulants and proteolytic inhibitors as described by De Haen et al. (29) . The radioimmunoassays for IRI (30) , IRG (27) , and SLI (27) 
Statistical analysis
Analysis of hormone outputs were done using the Dunnett's test for multiple comparisons versus baseline on an analysis of variance with repeated measures. Significance was accepted at the 5% level throughout. All results are expressed as mean±SEM.
Results
Experimental protocol I: four step glucose infusion
Responses to arginine. To determine if the alloxan exposure was sufficient to damage the majority of B cells in the ventral lobe of the pancreas, we measured and compared the integrated acute hormone responses with an arginine bolus (5 g i.v.) from the ventral lobe of either alloxan-treated (n = 6) or control (n = 7) dogs. The integrated acute ventral lobe insulin responses to arginine (2-15 min) were markedly impaired in alloxan-treated dogs compared with the control animals (10.5±2.4 vs. 73.2±15.7 mU; P < 0.005; i±SEM). In contrast, the integrated acute glucagon response to arginine in control animals (5.1±1.3 ng) was not different than that in alloxantreated dogs (4.1 ± 1.0 ng). The integrated acute somatostatin response to arginine appeared to be higher in alloxan-treated as compared with control animals (8.3±1.5 vs. 4.8±1.1 pmol), but the difference was not significant P = 0.07). Glucose infusion. To determine ifthe momentary clamping ofthe dorsal pancreas protected enough B cells to prevent fasting hyperglycemia in the alloxan-treated animals, glucose values were measured in both control and alloxan-treated animals both before and during surgery. Arterial plasma glucose was 104±8 mg/dl (mean±SE) in control animals and 102±3 mg/dl in alloxan-treated dogs both before anesthesia (P = NS). Mean glucose after induction of anesthesia and surgery was 112±2 mg/dl in controls and 125±9 mg/dl in alloxan-treated animals. Glucose was infused at four different rates (steps 1-4, see Methods) to determine the amount ofhyperglycemia necessary to suppress glucagon secretion in both control and alloxantreated animals. Mean (±SE) plasma glucose in control dogs at step one was 123±2 mg/dl; step two, 153±6 mg/dl; step three, 212±14 mg/dl; and step four, 468±45 mg/dl (Fig. 1) . In alloxan-treated dogs the mean plasma glucose were significantly higher (P < 0.01) than in control dogs at each step. At step one, glucose in the alloxan-treated dogs was 146±10 mg/dl; step two, 185+12 mg/dl; step three, 273±13 mg/dl; and step four, 594±51 mg/dl (Fig. 1) .
Insulin responses. To determine the magnitude of the ventral B cell response to the four steps of glucose in both control and in the alloxan-treated animals, we measured IRI output from the ventral lobe ofthe pancreas in both groups (see Fig. 2 ). In control dogs, the mean basal IRI output from the ventral lobe was 6.7±1.9 mU/min. At step one IRI output rose to a steady level of 11.6±2.7 mU/min; step two, 25.7±6.1 mU/ min; step three, 54.2±12 mU/min; and step four, 77.5±25.9 mU/min. In contrast, in alloxan-treated dogs the mean basal IRI output from the ventral lobe was 2.7±0.6 mU/min, rose to 4.5±1 at step one, and then stabilized at 5.6±1.4, 5.6±1.2, and 5.2±1 mU/min at steps two through four. Thus, the IRI outputs were significantly (P < 0.002) and markedly lower in the alloxan-treated dogs both before and during the glucose infusions.
Glucagon response. To determine which step ofglucose infusion was sufficient to suppress glucagon secretion we measured ventral lobe IRG output before and during the four steps ofglucose infusions (see Fig. 3 ). In control dogs, the mean basal IRG output from the ventral lobe was 1.24±0.36 ng/min. At step one there was no significant change in IRG output (-6±9%) but output decreased significantly to -49±4, -50±8, and -62±6% ofbasal at steps two, three, and four, respectively (all P < 0.001). In alloxan-treated dogs, the basal IRG output was 1.20±0.32 ng/min. In contrast to the control dogs, there was no significant change from baseline IRG at steps one through four, although there appeared to be a small progressive trend downward (+14±15, -3±19, -24±15, and -29±16%) (P = NS). Thus, the control dogs had an abrupt suppression of glucagon at step 2 (glucose, 153±6 mg/dl) followed by a small further decline in glucagon secretion. In the alloxan-treated dogs this abrupt suppression was absent; however, there was a slow downward trend of glucagon secretion with increasing glucose levels that did not achieve statistical significance.
Somatostatin response. To determine if the suppression of glucagon secretion in control dogs was indirectly due to stimulation of pancreatic somatostatin secretion by hyperglycemia, we measured ventral lobe SLI output during the four glucose steps (see Fig. 4 ). In control dogs, the mean basal SLI output from the ventral lobe was 2.4±0.8 pmol/min. SLI output did not rise significantly above baseline at step one (0±8%), step two (6±9%), or step three (39±12%) despite the significant suppression ofglucagon secretion at step 2. At step four SLI output rose significantly (+87±28%) (P < 0.01). In the alloxan-treated animals, the basal SLI output was 2.6±0.4 pmol/min, not different from control animals. However, no significant change in To determine the importance of islet insulin per se in the response ofthe A cells to hyperglycemia, we infused high concentrations of insulin into the pancreatic artery supplying the alloxan-treated ventral lobe of the pancreas and then infused glucose intravenously at the two highest rates of the previous protocol (steps three and four).
Glucose values. Basal values after induction of anesthesia
and surgery were 116±4.5 mg/dl. Mean (±SE) plasma glucose during insulin infusion alone was 112±2.5 mg/dl, plasma glucose at step three was 185±19.4 mg/dl, and step four was 430±41.8 mg/dl (see Fig. 5 ). Insulin responses. During the first 25 min of intra-pancreatic insulin infusion, calculated IRI output rose to 439±126 mU/min, more than 10-fold higher than the endogenous insulin output seen in control animals in protocol I, step 2 (see Methods). Calculated IRI output during both steps of glucose infusion, step three (553±92 mU/min) and step four (599±1 1 1 mU/min), was not significantly different than during infusion of insulin alone.
Glucagon responses. In these alloxan-treated dogs the basal IRG output was 1.5±0.45 ng/min. In response to intrapancreatic insulin infusion alone, IRG output did not change significantly (+4±15% from baseline). However, IRG output decreased significantly when glucose was infused intravenously during intrapancreatic insulin infusion. IRG output decreased by -42± 10% (P < 0.05) from baseline during glucose step three and by -68±5% (P < 0.01) from baseline during glucose step four (see Fig. 6 ). Somatostatin responses. To determine if restored glucagon suppression by hyperglycemia coincided with restoration ofthe pancreatic somatostatin response to hyperglycemia, ventral lobe SLI output was measured. In these alloxan-treated dogs, the basal SLI output was 1.4±0.3 pmol/min. There was no significant increase in SLI output after infusion ofinsulin alone (+ 16±22%) or after the step 3 glucose infusion (+32±29%). There was, however, a significant increase of ventral lobe SLI output during step 4 glucose infusion (+ 102±46%) (P < 0.05) (Fig. 7) .
Discussion
This study was designed to determine the mechanism of the insensitivity ofthe islet A cell to the suppressive effects ofhyperglycemia in insulin-deficient animals. Specifically, we sought to determine if local insulin deficiency, in the absence of chronic hyperglycemia, could produce such insensitivity. Further, we sought to determine whether the presumably large and rapid increases oflocal insulin that normally accompany acute hyperglycemia in noninsulin-deficient animals suppress the A cell directly, or whether high local levels ofinsulin simply allow glucose to suppress the A cell. Finally, we also carefully evaluated the potential role ofpancreatic somatostatin in such glucagon suppression by examining the dose-response relation between glucose-induced stimulation ofpancreatic secretion and glucose-induced suppression of pancreatic glucagon secretion (16, 18) . Alleviation of the chronic hyperglycemia by insulin treatment or phloridzin prevents these B cell secretory defects (19, 20) . Additionally, mild chronic hyperglycemia alters the A cell response to acute hypoglycemia (31) . Thus, it is likely that the chronic hyperglycemia of diabetes contributes to the insensitivity of the A cell. However, the question addressed in this study concerns the role of local insulin deficiency per se. To answer that question it was necessary to avoid the complication of chronic hyperglycemia while still producing insulin deficiency.
In this study local insulin deficiency was produced in the ventral portion of the canine pancreas by using a modification of the technique of Gomori and Goldner (23). This approach takes advantage of the very short half-life of alloxan in blood (23, 26) . By briefly clamping the vascular supply to the dorsal lobe of the pancreas for 2 min, we were able to isolate it from the B cell toxic effects of systemically injected alloxan and at the same time destroy the B cells in the unprotected ventral lobe. Sufficient B cells were protected in the dorsal lobe to maintain fasting normoglycemia, though under conditions of anesthesia and surgical stress, plasma glucose levels in the alloxan treated dogs were slightly higher than controls. In contrast, severe B cell destruction occurred in the ventral lobe as evidenced by markedly diminished ventral lobe insulin output in response to both arginine and glucose. Thus, the model apparently fulfilled the dual goals oflocal insulin deficiency without the chronic severe hyperglycemia usually associated with this degree of insulin deficiency.
The data from protocol I demonstrate that local intra-islet insulin deficiency is associated with impaired glucagon suppression by acute hyperglycemia. For (26, 36) .
The data in this study support that view because the basal and arginine-stimulated glucagon and somatostatin outputs in the alloxan-treated animals were not lower than those from control animals. Additionally, repleting insulin to the pancreas restored the ability of the alloxan-exposed A and D cells to respond normally to acute hyperglycemia.
Alternatively, local insulin deficiency could have prevented the rise of somatostatin and by this mechanism prevent suppression of glucagon secretion. However, in the control animals the acute suppression of glucagon occurred at step two (glucose levels -150 mg/dl) and significant stimulation of somatostatin secretion occurred only by step 4 (glucose levels > 400 mg/dl). Thus, increased somatostatin secretion is probably not the cause of this particular suppression of glucagon secretion. This observation is in complete agreement with earlier dose-response studies of Sorensen and Elde performed in the isolated rat pancreas (4) . It may, however, appear to be in conflict with previous work from our laboratory (12, 27 
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without hyperglycemia, suppressed glucagon secretion and whether somatostatin responses were restored.
In these studies, local insulin infusion into the B cell-deficient lobe did not, by itself, cause any change in IRG secretion, suggesting that high levels of intra-islet insulin do not directly mediate suppression of the A cell. This finding contrasts with two previous studies. In one study, Starke (3) noted a fall in IRG with a peripheral infusion of insulin at normoglycemia; however, this fall in IRG could have been due to insulin's suppressive effect on endogenous glucagon secretagogues such as plasma amino acids. Secondly, Maruyama (1 1) observed an increase in IRG secretion with acute immuneoneutrilization of intra-islet insulin in the isolated perfused pancreas. These results are harder to reconcile with our data. One possibility is that the chronic local insulin deficiency in our model renders the A cells insensitive to the direct suppressive effect of the short term insulin infusion. If so, then a time-dependent direct effect ofinsulin may have contributed to the late suppression of glucagon secretion during hyperglycemia.
When hyperglycemia was induced during the intra-islet insulin repletion, IRG secretion was suppressed, just as in control animals. We therefore conclude that high intra-islet levels of insulin allow glucose to directly suppress glucagon secretion in response to acute hyperglycemia. Studies ofother workers have suggested that insulin is necessary for the suppression ofglucagon by glucose. In high concentrations, insulin has been reported to inhibit glucagon secretion both in vivo and in vitro (9-11, 37, 38) . Retrograde perfusion studies designed to prevent the exposure ofthe A cell to high levels ofintra-islet insulin also prevented IRG suppression with hyperglycemia (6), and neutralization of insulin by a high affinity anti-insulin antiserum stimulated glucagon release in both the isolated rat (39) and dog pancreas (40) . The demonstration that blood flow is from the central B cell core of the islet to the D and A cells in the mantle of the islet (15) suggests that the A and D cells are usually exposed to very high levels of insulin. In contrast, the data ofthis study suggest that these high levels ofinsulin are, by themselves, not sufficient to inhibit glucagon secretion, but are needed to maintain the glucose sensitivity of the A cells.
These data also demonstrate that the pancreatic somatostatin response to hyperglycemia is lost during chronic local insulin deficiency. This finding is in agreement with those of Hermansen (41) and Trimble (42) who found that acute hyperglycemia did not stimulate somatostatin secretion in either the diabetic dog pancreas (41) or diabetic rat islets (42) , respectively. It is unlikely that the insensitivity ofthe D cell is due to a lack of direct effect of insulin on the D cell, as our data, and those of others (41) (42) (43) (44) , suggest that exogenous insulin at normoglycemia does not stimulate somatostatin secretion. Nevertheless, it remains possible that a stimulatory effect of insulin on the D cell may have occurred in our study after a longer period of insulin infusion.
This study did demonstrate that intra-islet insulin restored the stimulation of somatostatin secretion by acute hyperglycemia, suggesting that the normal somatostatin response to acute hyperglycemia requires the presence ofhigh levels ofintra-islet insulin. This finding contrasts with that of Hermansen who found that the addition of insulin to the diabetic pancreas failed to reverse the deficit in somatostatin secretion (41) . However, we replaced insulin to achieve pancreatic vein insulin concentrations 10-to 20-fold higher than those ofHermansen. Further, the 3 d ofdiabetic hyperglycemia present in Hermansen's study may have been sufficient to render the D cell insensitive to acute hyperglycemia (41) . This interpretation is supported by the study of Trimble et al., in which insulin treatment ofchronically diabetic rats restored the ability ofthe islets to respond to acute hyperglycemia in vitro (42) . However, the normalized somatostatin response seen in Trimble's study occurred in insulin-deficient rat islets (42) , and thus appears to be in direct contrast to our finding that high rates of insulin infusion are needed to restore the D cell's secretory response to glucose. The reason for this discrepancy remains unclear.
In conclusion, this study was designed to determine the mechanism of the insensitivity ofthe islet A cell to the suppressive effects of hyperglycemia in insulin-deficient animals. We have shown that in the presence of local insulin deficiency and the absence ofchronic hyperglycemia, the A 
